Our Team
Tuomo Pätsi
Executive Chairman of the Board
Tuomo Pätsi, is a senior biotech executive with extensive international experience in building, launching and commercializing novel treatments, many of which have become standards of care.
Tuomo has over 30 years of experience working in the biotech and pharmaceutical industries. Until 2022 he served as the Executive Vice President of Seagen, a US-based cancer-focused biotechnology company specialized in Antibody Drug Conjugate technology.
Between 2006 and 2020, he served in various capacities at Celgene, which was later acquired by Bristol-Myers Squibb, including as the President of the EMEA region and Worldwide Markets and President of European and International Operations, engaged primarily in the development, and commercialization of therapies for the treatment of cancer.
Prior to his work at Celgene, Tuomo served as Vice President of Europe for Human Genome Sciences, and over a period of 11 years in roles of increasing responsibility at Amgen, in Europe and the United States. Tuomo is a board member of Aurealis Therapeutics AG (private), Aqsens Health Ltd. (private), chairman of Faron Pharmaceuticals Ltd. (AIM London: FARN, Nasdaq Helsinki First North: FARON), board member of Psyon Games Ltd. (private), co-founder of Rigi Therapeutics AG (private) and chairman of Notable Labs Inc. (Nasdaq: NTBL).
Tuomo is a registered pharmacist and holds an MSc in pharmacology from the School of Pharmacy, Helsinki University.
Christophe Bonny
Co-founder, Board member
Christophe Bonny, PhD. is an accomplished science leader with a focus on peptide drug discovery.
Christophe Bonny, PhD. is an accomplished science leader with a focus on peptide drug discovery.
Christophe has over 30 years’ experience in the field of molecular biology and signalling pathways, has authored over 80 scientific publications and is an inventor on >30 patents. He works as CSO of Xbiome in Shenzhen, China since 2023. He discovered D-JNKI, a cell permeable peptide inhibitor of the JNK protein, which formed the basis for the creation of the biotechnology company Xigen SA in 2003. In 2005, he received the Pfizer Research Prize for this discovery.
Between 2016 and 2023, he was CSO of Enterome BioScience in Paris France.
Between 2012 and 2016, he was CSO of Bicycle Therapeutics in Cambridge UK. Between 2006 and 2011, he was CSO of Xigen SA (Switzerland). Previously, he also held the position of Head of Research of the Medical Genetics unit at Lausanne University Hospital (Switzerland) and prior to this was a Research Fellow at Northwestern University (US).
Christophe obtained a PhD from the University of Neuchâtel (Switzerland), and completed a business and entrepreneurship program at Babson College (US).
Nicolas Marsault
Finance
Nicolas Marsault, brings over 15 years of finance executive experience in healthcare and industrial finance.
Nicolas Marsault, brings over 15 years of finance executive experience in healthcare and industrial finance.
Nicolas is the Chief Financial Officer of Step Pharma since October 2021. Before joining Step, he was CFO at Prexton Therapeutics which was subsequently acquired by Lundbeck. Earlier roles include CFO of Endosense, a MedTech start-up company acquired by St Jude Medical in 2013, and various managerial positions within Merck Serono’s controlling, forecasting and internal audit departments, where he also played a significant role in business development. Nicolas is the founder of Bees4You, a company in the field of sustainable development.
Nicolas holds an Engineering degree from Ecole des Mines de Paris, France, and a master’s degree in mechanical engineering from Northwestern University, Chicago, USA.
Peter Greaney
Business Development
Peter Greaney, PhD. is a global deal-maker and is passionate about advancing innovative science for the benefit of patients.
Peter Greaney, PhD. is a global deal-maker and is passionate about advancing innovative science for the benefit of patients.
Peter has international experience in building successful biotech companies. He has been responsible for the successful execution of numerous business development deals in his career and has experience in a wide array of deal structures. He is experienced in seeking new business opportunities, leading negotiations, and managing research collaborations.
At ADC Therapeutics, Peter was the Head of Corporate Development and played an integral role transforming the company from a private R&D biotech to a NYSE listed public biotech with a commercial therapeutic product. Prior to ADC Therapeutics, Peter held medical and business positions of increasing responsibility at Celgene in Switzerland and the United States. He held roles in Business Development, Strategy & Operations, Market Research & Business Intelligence, Medical Affairs, and Medical Development.
Prior to Celgene, Peter was a Preclinical Senior Scientist at Apoxis, S.A. in Switzerland and an intern scientist at Servier, Paris.
Peter graduated with a Bachelor of Science in Cell Biology from the University of East Anglia and a PhD in Molecular and Cellular Biology from the University of Nottingham (supported by Servier).
Kevin Lynch
Medical
Kevin Lynch, MB, BS. is inspired by the opportunity to develop transformative medicines for patients.
Kevin Lynch, MB, BS. is inspired by the opportunity to develop transformative medicines for patients.
He has lived and worked in Australia, Asia, UK and Switzerland, operating in both small, start-up environments as well as large, multi-nationals.
Kevin was Chief Medical Expert during Antengene’s formative years and then through a period of extreme growth as Chief Medical Officer. He supervised their broad clinical program with Xpovio (Selinexor) in Asia-Pacific, as well as an extensive first-in-human early development program.
During over 11 years at Celgene Kevin was closely involved in the successful clinical development and registration of Revlimid (lenalidomide), Pomalyst (pomalidomide), Vidaza (azacitidine), Onureg (oral azacitidine) and Idhifa (enasidinib).
During his 10 years with Novartis, as one of the inaugural Oncology Medical Directors for the company, he played a key role in the development and approvals of multiple transformative drugs including Glivec (imatinib), Tasigna (nilotinib), Zometa (zoledronic acid), Femara (letrozole) and Exjade (deferasirox).
Kevin graduated B Med Sci and MB, BS from the University of Tasmania in Australia. His post-graduate training in Pharmaceutical Medicine was completed in the UK, where he gained his Fellowship of the Faculty of Pharmaceutical Medicine.
Gertjan Bartlema
Operations
Gertjan Bartlema, thrives on building teams and creating collaborative impact. He is a pragmatic and authentic leader with broad operational biotech experience.
Gertjan Bartlema, thrives on building teams and creating collaborative impact. He is a pragmatic and authentic leader with broad operational biotech experience.
Gertjan was the CEO of VICO Therapeutics BV a privately held Netherlands based company focused on antisense oligonucleotide-based RNA modulating therapeutics for rare CNS diseases.
During his 20+ years global biotech career he was part of emerging organizations and new capability building, including healthcare big data/real-world data and marketing & sales excellence capabilities. During his 12 years at Celgene (US and Switzerland), he was part of the European management team, the corporate business development team that acquired Abraxis and the information knowledge utilization team that established an industry leading network of real-world data and technology partnerships including COTA, Inc., Flatiron Health, and GNS Healthcare and strategic partnerships with IBM Watson, Health2047, and M2Gen.
Other roles he held during his career include Strategy, Marketing & Sales Excellence, Business Planning and Financial Planning & Analysis. He started his biotech career at Amgen Europe based in Lucerne, Switzerland. Over a nine year period at Amgen was based in Thousand Oaks, CA and Switzerland.
Gertjan holds a Masters in Economics from Maastricht University, the Netherlands and has dual Dutch and Swiss citizenship. He lives with his family in Switzerland.
